Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Bio Manufacturers Poised To Follow Senate Victory With House Win
"A veteran California lawmaker with ties to the biotechnology industry said she thinks her proposal to protect brand-name biologic makers has enough support to carry in the House Energy and Commerce Committee," Dow Jones Newswires/Wall Street Journal reports. The proposal, by Rep. Anna Eshoo, D-Calif., would protect brand-name biologic products from competition for 12 years. A similar proposal cleared the Senate health committee earlier this week.
generic viagra online
Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus" proprietary protein crystallization technology. ALTU-238 is a ready-to-use liquid suspension of crystallized rhGH that preserves the structure of the rhGH molecule without the need for pegylation, polymerization, or encapsulation and enables administration through a fine gauge needle. The Phase 2 ALTU-238 pediatric trial is being conducted in approximately 18 clinical sites in the U.S. and targets enrolling 36 growth hormone deficient pediatric patients. ALTU-238 has been studied in a series of Phase 1 and Phase 2 studies in healthy and GH deficiency adults.
News of the day
Dysport Proves Safe, Effective Anti-Wrinkle Treatment, Plastic Surgeons Find
The new anti-wrinkle facial filler Dysport, which could be used as an alternative to Botox, noticeably reduced frown lines between the eyes, according to users and independent reviewers in a study involving plastic surgeons at UT Southwestern Medical Center.
Endocrinology

The Characteristics Of Clarithromycin-Resistant Helicobacter pylori

Clarithromycin is currently one of the antibiotics used for eradication of Helicobacter pylori. However, reports of H. pylori resistance to this antibiotic are increasing worldwide. Clarithromycin resistance has been attributed to the presence of mutations in the 23S rRNA gene, a component of the ribosome that is the protein manufacturing machinery of all living cells. There is little information on the prevalence and characteristics of clarithromycin resistance in H. pylori strains isolated from Malaysian patients. In a research article published in the World Journal of Gastroenterology, the authors determined the prevalence of resistance and characterized the types of mutations present in their resistant strains. In this study conducted by Norazah et al on strains isolated in Malaysia, a low prevalence of clarithromycin-resistant strains was noted. Transitions of adenine to guanine at positions 2142 and 2143 of the 23S rRNA of H. pylori were the main mutations found in clarithromycin-resistant isolates. The A2142G and 2143G mutations of 23S rRNA genes in these strains can be detected easily by restriction fragment length polymorphism (RFLP) analysis of the PCR product of the 23S rRNA genes, using MboII or BsaI restriction enzymes. This eliminates the need to detect these mutations by sequencing. The result of the study demonstrates that clarithromycin resistance is present among local strains. However, even though it is an uncommon occurrence, the possibility of the patient being infected with a resistant strain should be considered if the patient does not respond to treatment with clarithromycin, so that an alternative treatment can be given. The ability to detect clarithromycin resistance by molecular methods such as RFLP showed that this rapid method has the potential to be used as a diagnostic tool. Reference: Ahmad N, Zakaria WR, Abdullah SA, Mohamed R. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. World Journal of Gastroenterology 2009; 15(25):3161-3165 http://www.wjgnet.com/1007-9327/15/3161.asp Correspondence to: Dr. Norazah Ahmad, Bacteriology Unit, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia. Lin Tian World Journal of Gastroenterology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009